An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
Status:
Terminated
Trial end date:
2013-07-16
Target enrollment:
Participant gender:
Summary
The primary purpose of this extension study is to assess the long-term safety and
tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and
NCT01227265 [P07037] with moderate to severe Parkinson's Disease (PD). The study will also
characterize the long-term efficacy of preladenant in participants with PD.
Participants will continue to receive their stable regimen of levodopa (L-dopa) plus any
adjunct medications during the study as prescribed by their physician. Several classes of
adjunct medications may be used, including Amantadine, anticholinergics, dopa decarboxylase
inhibitors, and dopamine agonists.